Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 65 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
PolyPeptide from Braine-l'Alleud, company number BE0879346768, closed financial year 2025 with a result of € 7.2 million after tax. For that financial year PolyPeptide recorded revenue of € 156.1 million and equity of € 103.8 million. Compared with financial year 2024, the result moved from € -3.2 million to € 7.2 million. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 11, 2026.
€ 103.8 million
▲ 7% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 7.2 million
▲ still € 3.2 million loss in 2024
Profit after tax over the fiscal year.
€ 87,135
▼ 72% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 63.6 million.
People and assets in 2025
485
▲ 16.9 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 56.8 million
▲ 11% vs 2024
€ 117,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 19.6 million
▲ 85% vs 2024
Of which on lease € 3.5 million.
Debts at end 2025
€ 129.2 million
▲ 14% vs 2024
€ 583,826 is repaid this year. At this pace the long-term loan is gone in ≈ 221 years.
€ 74.2 million
▲ 46% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 320 days on average.
€ 15.7 million
▲ 69% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 64,079,041 | € 98,658,265 | € 127,937,096 | € 156,109,657 | ▲ 22% |
| Profit after taxes | € 4,902,991 | € 5,445,372 | € -3,166,254 | € 7,243,641 | ▲ € 10.4 million |
| Equity | € 92,746,689 | € 98,141,387 | € 96,606,018 | € 103,798,985 | ▲ 7% |
| Total debts | € 52,563,130 | € 110,394,386 | € 173,512,455 | € 226,319,038 | ▲ 30% |
| Cash | € 4,299,398 | € 2,055,745 | € 307,106 | € 87,135 | ▼ 72% |
| Land & buildings | € 11,375,561 | € 12,928,918 | € 25,907,847 | € 27,431,870 | ▲ 6% |
| Retained profit | € 52,353,965 | € 57,799,337 | € 56,365,316 | € 63,608,958 | ▲ 13% |
| Bank debt | € 28,412,269 | € 68,665,780 | € 113,094,311 | € 129,240,917 | ▲ 14% |
| Balance sheet total | € 145,793,231 | € 209,648,726 | € 271,065,115 | € 331,744,197 | ▲ 22% |
| Employees (FTE) | 317.2 | 394 | 468.1 | 485 | ▲ 16.9 |
Key figures of PolyPeptide, fiscal years 2021 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PolyPeptide?
What happened at PolyPeptide in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 7.2 million. Source: NBB ↗
- New establishment in Beersel. KBO
- Polypeptide Laboratories Holding AB became a director. NBB
- New establishment in Braine-l'Alleud. KBO
- Start of the company according to the CBE. KBO
In short
From € 4.9 million profit in 2021 to € 7.2 million profit in 2025.
Paid € 4.2 million in corporate taxes since 2021.
Best year ever: 2025, with € 7.2 million profit.
A new publication or filing at PolyPeptide? We notify you, reason included.
Follow PolyPeptideDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind PolyPeptide is Polypeptide Laboratories Holding AB. The shares are held by Polypeptide Laboratories Holding (PPL) AB (100%).
Directors
According to the 2025 annual accounts
Polypeptide Laboratories Holding AB
Director · represented by Raoul Bernhardt
since 2023
Shareholders
Polypeptide Laboratories Holding (PPL) AB
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Chaussée de Tubize 297
1420 Braine-l'Alleud
Jozef Huysmanslaan 53
1651 Beersel
Active since 1 January 2024
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0879.346.768
- VAT number
- BE 0879.346.768
- Registered office
- Chaussée de Tubize 297, 1420 Braine-l'Alleud
- Names & denominations
- PolyPeptide
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 14 February 2006
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Vervaardiging van farmaceutische grondstoffen
Vervaardiging van andere chemische producten, neg
Vervaardiging van andere anorganische chemische basisproducten
Vervaardiging van geneesmiddelen
Vervaardiging van verdelgingsmiddelen, ontsmettingsmiddelen en andere chemische producten voor de landbouw
Vervaardiging van andere organische chemische basisproducten
Vervaardiging van overige organische chemische basisproducten
Vervaardiging van overige anorganische chemische basisproducten
+2